Vascular Biogenics Ltd. (VBLT)
Dopo ore:
| Chiusura precedente | 0,2368 |
| Aperto | 0,2361 |
| Denaro | 0,2260 x 1800 |
| Lettera | 0,2290 x 1800 |
| Min-Max giorno | 0,2220 - 0,2360 |
| Intervallo di 52 settimane | 0,2100 - 2,5400 |
| Volume | |
| Media Volume | 3.180.927 |
| Capitalizzazione | 15,839M |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,4690 |
| Prossima data utili | 14 nov 2022 - 18 nov 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 5,00 |
- GlobeNewswire
VBL Therapeutics Announces Second Quarter 2022 Financial Results and Corporate Process to Explore Strategic Options
Exploring strategic options to maximize shareholder value; engaged Chardan as financial advisorTEL AVIV, Israel and NEW YORK, Aug. 15, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, today announced financial results for the second quarter ended June 30, 2022 and provided a corporate update. “Following our announcement in July that the Phase 3 OVAL trial evaluating ofra-vec did not meet its primary
- GlobeNewswire
VBL Therapeutics Announces Workforce Reduction
TEL AVIV, Israel and NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases, today announced an organizational streamlining designed to reduce operating expenses and preserve capital. As a result, VBL will reduce its workforce by approximately 35%. As part of the cost cutting initiatives, Dr. Ron Cohen, Dr. Bennett Shapiro and Ms. Alison Finger resigned from the board of directo
- GlobeNewswire
VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer
- Trial Did Not Meet Statistical Significance on Improvement in Primary Endpoints of Progression Free Survival (PFS) or Overall Survival (OS) -TEL AVIV, Israel and NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases, today announced top-line data from the Phase 3 OVAL clinical trial of ofra-vec (ofranergene obadenovec; VB-111) in platinum-resistant ovarian cancer. The trial d
